The Biotechnology Innovation Organization (BIO) released a policy proposal, “BioAdvance: Securing America’s Biotech Century,” arguing Congress and the Trump administration should enact seven priorities to keep the U.S. “global leader” status in biotechnology. BIO’s plan calls for speeding drug development, strengthening clinical trial infrastructure, improving investment conditions, and expanding biomedical research support, including a proposed White House Office of Biotechnology. BIO’s release also cites China’s accelerating clinical trial footprint and earlier-stage research expansion as reasons the U.S. must respond with coordinated policy rather than incremental changes. The lobbying group warned that approaches focused on restricting investments cannot solve the competitiveness gap. The proposal lands amid ongoing U.S.-China biotech debate over deal scrutiny, with policy-makers weighing investment and national-security concerns alongside the need for innovation throughput.